{"title":"Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis","authors":"Adam Mead MRCPath","doi":"10.1002/fps.100","DOIUrl":null,"url":null,"abstract":"<p>Ruxolitinib is an orally administered JAK2 inhibitor for the treatment of disease-related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia. In our Drug profile Dr Adam Mead presents the clinical data relating to its efficacy and adverse events and comments on its place in therapy. Copyright © 2013 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 3","pages":"20-23"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.100","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.100","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Ruxolitinib is an orally administered JAK2 inhibitor for the treatment of disease-related splenomegaly or symptoms in primary myelofibrosis or myelofibrosis due to polycythaemia vera or essential thrombocythaemia. In our Drug profile Dr Adam Mead presents the clinical data relating to its efficacy and adverse events and comments on its place in therapy. Copyright © 2013 John Wiley & Sons, Ltd.
Ruxolitinib: JAK2抑制剂治疗骨髓纤维化
Ruxolitinib是一种口服JAK2抑制剂，用于治疗原发性骨髓纤维化或真性红细胞增多症或原发性血小板增多症引起的原发性骨髓纤维化的疾病相关性脾肿大或症状。在我们的药物简介中，Adam Mead博士介绍了有关其疗效和不良事件的临床数据，并对其在治疗中的地位进行了评论。版权所有©2013 John Wiley &儿子,有限公司
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
